[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476049":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":52,"collaborators":30,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":30,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"CNAO National Center of Oncological Hadrontherapy","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"carbon ion radiotherapy","EXPERIMENTAL","Patients affected by pelvic recurrence of gynecological cancer, who had not undergone to previous pelvic irradiation, will be enrolled on this study. After enrollment, patients undergo baseline exams, simulation CT and MRI and then carbon ion radiation therapy treatment will be performed, according to trial indications.",[13],"Radiation: carbon ion radiation therapy CIRT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","carbon ion radiation therapy CIRT","CIRT: The low-dose CTV (clinical target volume) will receive a total dose of 43 GyRBE in 10 fractions, 4 fractions per week. The high-dose CTV will receive a total dose of 68.8 GyRBE in 16 fractions, 4 fractions per week.\n\nThe expected duration of treatment is 4 weeks, 4 fractions per week. Treatments lasting longer than 6 weeks, or with less than 6 fractions administered on 14 consecutive days, will not be considered acceptable.\n\nImmunotherapy: Patients will undergo immunotherapy after carbon ion radiation therapy (CIRT) up to maximum response and\u002For up to tolerance. The concomitant association of immunotherapy is not envisaged in this protocol.",[9],[21],"immunotherapy",[23],{"name":24,"affiliation":5,"role":25},"Amelia Barcellini, MD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","0039 0382078501",null,"amelia.barcellini@cnao.it",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Cristina Bono, MSc","0382078613","cristina.bono@cnao.it",[37],{"facility":38,"status":39,"city":40,"state":30,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CNAO","RECRUITING","Pavia","27100","Italy","IT",{"type":45,"coordinates":46},"Point",[47,48],9.15917,45.19205,{"lat":48,"lon":47},[51],{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},{"type":53,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100476049","carbon-ion-radiation-therapy-in-the-treatment-of-mucous-melanomas-of-the-female-lower-genital-tract-100476049",false,"NCT05478876","Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract","CNAO 40-2020 C CYCLE \"Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract\" \"Radioterapia Con Ioni Carbonio Per il Trattamento Dei Melanomi Mucosi Ginecologici\"","CYCLE","Inclusion Criteria:\n\n* Histological diagnosis\n* Absence of skin extension\n* N + (only if confined to the groin and pelvis)\n* Age between 20-80 years\n* ECOG 0-2\n* No evidence of metastasis\n* At least 5 mm away with rectum and bladder wall\n* No previous RT\n* Written informed consent\n* Patient's ability to understand the characteristics and consequences of the clinical trial\n* Molecular characterization\u002F mutational state\n* Disease staging (baseline exams)\n\nExclusion Criteria:\n\n* Hip prosthesis, or metal prostheses or any other condition that prevents adequate imaging to identify the target volume and calculate the dose in the treatment plan\n* Psychic or other disorders that may prevent informed consent\n* Previous invasive tumor unless patient has been disease free for at least 3 years\n* Contraindication to MRI\n* Pregnancy or breastfeeding in progress","FEMALE","20 Years","80 Years",{"count":66,"type":67},9,"ESTIMATED","INTERVENTIONAL",[70],"NA","The present monocentric prospective phase 2 study aims to reproduce the results obtained at NIRS thus offering the possibility of obtaining a promising rate of progression-free survival (PFS) and local control (LC) in patients diagnosed with mucosal melanoma of lower genital tract. Systemic treatment with immunotherapy is not the subject of this study but is allowed both in the neoadjuvant and sequential regimens.\n\nMelanomas have always been considered poorly radiosensitive. It is now accepted that high LET (Linear Energy Transfer) particle beams, such as carbon ions, can offer a biological advantage, compared to photons treatment, in radio-resistant neoplasms treatment, thanks to their higher biological efficacy (RBE) against tumours with a low α\u002F ß ratio. In addition, carbon ions have the physical advantage of an inverted depth deposition profile compared to photons, allowing then a steep dose gradients that ensure increased sparing of adjacent healthy organs at risk (OARs).",[73,74],"Malignant Melanoma","Gynecologic Cancer",[76],"hadrontherapy, gynecological melanoma","2024-08-20",{"date":79,"type":80},"2024-08-21","ACTUAL",{"date":82,"type":80},"2020-09-03",{"date":84,"type":67},"2027-09",{"name":5,"class":6},1]